Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

Stanford researchers have discovered BRP, a naturally occurring peptide that suppresses appetite and promotes weight loss, ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Weight loss supplements are a big industry, but do they actually work? A dietitian explores the evidence, efficacy, and safety of common weight loss supplements.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...